Diffusion Pharmaceuticals

Diffusion Pharmaceuticals, a Virginia-based clinical-stage biotech company, has completed patient enrolment in a Phase II trial of an anti-cancer compound, trans sodium crocetinate (TSC).

A total of 56 patients with newly diagnosed primary brain cancer (glioblastoma multiforme or GBM) were recruited at 18 cancer institutions across the US.

The study will assess if the addition of TSC to the existing GBM standard-of-care therapies can significantly improve the survival times.

Diffusion Pharmaceuticals chief medical officer Dr David Jones said the speed of accrual for its GBM trial has been significant.

"This speaks to the huge unmet medical need in GBM and the desire of clinicians to identify much-needed new therapies and move them forward as rapidly as possible," Jones said.

"We are also quite pleased at the safety profile of TSC and believe this played a significant role in the rapid rate of patient enrolment."

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

After the completion of Phase I safety lead-in study, the open enrolment in the Phase II study was commenced in November 2012.

An independent Safety Monitoring Committee determined the absence of any dose-limiting toxicities and the tolerance of TSC in all patients in the Phase I study.

The company has opened a new financing round to raise funds to advance the clinical development.

Diffusion CEO David Kalergis said; "We expect most of it to be placed with our existing shareholders, although we may add several additional accredited investors from our network."

Photo: The Diffusion study will determine the efficacy of TSC when added to current standard-of-care treatment for GBM. Image Courtesy of CrystlBluPersuason.